Company intelligence / Profile preview

Shenzhen Geno-Immune Medical Institute

Shenzhen, Guangdong, Chinaszgimi.org ↗

Ownership: Private
Development stage: Phase 2

Overview

GIMI has over two decades of R&D in immune therapies. Its lead CAR-T programs are in Phase II for blood cancers and solid tumors. The institute’s fourth-generation ‘4SCAR’ CAR-T cells have demonstrated high safety profiles with no serious cytokine release syndrome or neurotoxicity reported to date. Early studies combining mesenchymal stem cells with CAR-Ts for autoimmune disease are ongoing.

Therapeutic areas: OncologyImmunologyHematology
Modalities: CAR-T cell therapyGene therapyCell therapyMesenchymal stem cells (MSCs)
Industry: Biotech

Drug pipeline

57 assets

DCvac

56 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on Shenzhen Geno-Immune Medical Institute.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Shenzhen Geno-Immune Medical Institute.

Explore the full profile